Chih-Chung Tseng

Title: Chih-Chung Tseng: Innovator in Neuropharmacology

Introduction

Chih-Chung Tseng is a notable inventor based in Aberdeen, GB. He has made significant contributions to the field of neuropharmacology, particularly through his innovative research and development of compounds that target specific receptors in the brain. With a total of 2 patents, Tseng's work has the potential to impact the treatment of various neurodegenerative diseases.

Latest Patents

Tseng's latest patents include groundbreaking work on modulators of AMPA receptor signaling. These compounds, described by the formula (I), have demonstrated utility in modulating AMPA receptor signaling, which may help prevent AMPA receptor-mediated toxicity. This research is particularly relevant for treating diseases where AMPA receptor activation contributes to neurodegeneration, such as multiple sclerosis. Another significant patent involves cannabinoid type 1 receptor modulators, which are indole derivatives of the formula (I). These modulators are beneficial in treating diseases where modulation of the cannabinoid receptor is advantageous, and the patent includes processes for their preparation, pharmaceutical compositions, and methods of use.

Career Highlights

Throughout his career, Tseng has worked with esteemed institutions, including the University Court of the University of Aberdeen and the University of Toronto. His research has not only advanced scientific understanding but also paved the way for potential therapeutic applications.

Collaborations

Some of Tseng's notable coworkers include Iain Robert Greig and Ruth Ross. Their collaborative efforts have contributed to the success of his research projects and the development of innovative solutions in neuropharmacology.

Conclusion

Chih-Chung Tseng's contributions to the field of neuropharmacology through his patents and collaborations highlight his role as a significant inventor. His work continues to inspire advancements in the treatment of neurodegenerative diseases.